NCT00446303 - A Phase II Study of Maintenance With Azacitidine in MDS Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions

Leukemia, Myelocytic, AcuteMyelodysplastic Syndromes

Interventions

DRUG

Azacitidine

"Azacitidine 60mg/m2 /d for 5 days every 28 days, for 24 months (parallel study to the ongoing NMDSG study.~Extension of maintenance in responders after 24 courses until relapse or death."

Trial Locations (25)

13273

Hopital Paoli Calmette, Marseille

14033

CHU de Caen, Caen

21034

CHU de Dijon, Dijon

31031

Hopital Purpan, Toulouse

33604

Hopital Haut Leveque, Pessac

35033

CHU Pontchaillou, Rennes

38043

CHU Albert Michallon, Grenoble

44093

Hopital Hotel Dieu, Nantes

49033

CHU Angers, Angers

51092

CHRU de Reims, Reims

54511

CHU Brabois, Vandœuvre-lès-Nancy

59057

CHRU Hurriez, Lille

67098

Hopital Hautepierre, Strasbourg

69437

Hopital Edouard Herriot, Lyon

75475

Hopital Saint Louis, Paris

75571

Hopital Saint Antoine, Paris

75679

Hopital Cochin, Paris

78000

CH Versailles, Versailles

80054

CHU d'Amiens, Amiens

84000

CH d'Avignon, Avignon

86021

Hopital Jean-Bernard, Poitiers

87046

CHRU de Limoges, Limoges

92140

Hopital d'Instruction des Armées Percy, Clamart

94000

Hopital Henri Mondor, Créteil

06202

Hopital Archet, Nice